Brentuximab vedotin, sold under the brand name Adcetris, is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.[4] The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seagen in the US.[5]
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^Cite error: The named reference Adcetris FDA label was invoked but never defined (see the help page).
^Cite error: The named reference Adcetris EPAR was invoked but never defined (see the help page).
^"Seattle Genetics Submits BLA to FDA for brentuximab vedotin in relapsed or refractory hodgkin lymphoma and systemic ALCL". Fierce Biotech. 28 February 2011.
^"Takeda and Millennium Announce Approval of Adcetris (Brentuximab Vedotin) in Switzerland". www.takedaoncology.com. Archived from the original on 4 June 2020. Retrieved 4 June 2020.
and 20 Related for: Brentuximab vedotin information
Brentuximabvedotin, sold under the brand name Adcetris, is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma...
enhancing antitumor activity. The company's flagship product Adcetris (brentuximabvedotin) is commercially available for four indications in more than 65 countries...
with PML on April 10, 2009.[citation needed] A boxed warning for brentuximabvedotin (Adcetris) was issued by the FDA on January 13, 2011 after two cases...
FDA approved therapeutic brentuximabvedotin (Adcetris). It is approved for use in: Hodgkin lymphoma (HL) (brentuximabvedotin) after failure of autologous...
drugs have been developed for relapsing and refractory HL patients; Brentuximabvedotin, a CD30 antibody conjugated with a cytotoxic component MMAE, and...
include itching, headache, nausea, diarrhea and low blood pressure. Brentuximabvedotin (trade name: Adcetris) is a CD30 targeted antibody-drug conjugate...
(cHL) who have failed autologous stem cell transplant (ASCT) and brentuximabvedotin (BV), or who are transplant-ineligible and have failed BV as monotherapy...
hematopoietic stem cell transplantation (auto-HSCT) and post-transplantation brentuximabvedotin. On 20 December 2017, the FDA granted approval to nivolumab for adjuvant...
acute myeloid leukemia. Two other drugs, trastuzumab emtansine and brentuximabvedotin, are both in late clinical trials, and the latter has been granted...
1014)" at ClinicalTrials.gov Clinical trial number NCT01979536 for "BrentuximabVedotin or Crizotinib and Combination Chemotherapy in Treating Patients With...
fluorescent dye) to a protein. Antibody-drug conjugates such as Brentuximabvedotin and Gemtuzumab ozogamicin are examples falling into this category...
Global Information
(what is this?) (verify)